argenx SE (EBR:ARGX)
524.20
+0.80 (0.15%)
Apr 17, 2025, 5:35 PM CET
argenx SE Employees
argenx SE had 1,599 employees as of December 31, 2024. The number of employees increased by 451 or 39.29% compared to the previous year.
Employees
1,599
Change (1Y)
451
Growth (1Y)
39.29%
Revenue / Employee
€1,358,062
Profits / Employee
€503,210
Market Cap
32.01B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UCB SA | 9,378 |
Fagron NV | 3,828 |
Ion Beam Applications | 2,145 |
Nyxoah | 184 |
Hyloris Pharmaceuticals | 49 |
Onward Medical | 99 |
Sequana Medical NV | 62 |
Celyad Oncology | 19 |
argenx SE News
- 7 days ago - FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - Benzinga
- 7 days ago - FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting - Benzinga
- 7 days ago - argenx Announces Annual General Meeting of Shareholders on May 27, 2025 - GlobeNewsWire
- 8 days ago - Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug - Investor's Business Daily
- 8 days ago - Argenx, Halozyme win FDA nod for Vyvgart Hytrulo prefilled syringe - Seeking Alpha
- 8 days ago - Why Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket - Benzinga
- 8 days ago - US FDA approves syringe version of Argenx's immune disorder drug - Reuters
- 8 days ago - argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire